Holen Sie sich die Stockscreener-App
8.60
3.69%
-0.34
Schlusskurs vom Vortag:
$8.94
Offen:
$8.97
24-Stunden-Volumen:
398.29K
Relative Volume:
0.46
Marktkapitalisierung:
$456.02M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.44M
KGV:
-9.6564
EPS:
-0.8906
Netto-Cashflow:
$-24.66M
1W Leistung:
+0.35%
1M Leistung:
-7.32%
6M Leistung:
+283.52%
1J Leistung:
+474.00%
1-Tages-Spanne:
$8.56
$9.31
1-Wochen-Bereich:
$8.13
$9.60
52-Wochen-Spanne:
$1.34
$11.61
Immix Biopharma Inc Stock (IMMX) Company Profile
Firmenname
Immix Biopharma Inc
Sektor
Branche
Telefon
(888) 958-1084
Adresse
11400 WEST OLYMPIC BLVD., LOS ANGELES
Compare IMMX vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IMMX
Immix Biopharma Inc
|
8.61 | 473.50M | 0 | -29.44M | -24.66M | -0.8906 |
VRTX
Vertex Pharmaceuticals Inc
|
433.68 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.51 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.60 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
331.03 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.76 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Immix Biopharma Inc Stock (IMMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-25 | Eingeleitet | Morgan Stanley | Overweight |
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2026-02-09 | Eingeleitet | Mizuho | Outperform |
Immix Biopharma Inc Aktie (IMMX) Neueste Nachrichten
Earnings Recap: Is Immix Biopharma Inc benefiting from innovation trendsNew Guidance & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Immix Biopharma, Inc. (NASDAQ:IMMX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Immix Biopharma Stock Price Forecast. Should You Buy IMMX? - stockinvest.us
Citizens Initiates Coverage of Immix Biopharma (IMMX) with Market Outperform Recommendation - MSN
IMMX PE Ratio & Valuation, Is IMMX Overvalued - Intellectia AI
Immix Biopharma — Momentum builds with NEXICART-2 progress - Smartkarma
Weekly Earnings: Is Immix Biopharma Inc stock a buy or sell2026 Chart Watch & Daily Entry Point Alerts - baoquankhu1.vn
Bear Alert: Is Immix Biopharma Inc benefiting from innovation trends2026 WrapUp & Smart Swing Trading Techniques - baoquankhu1.vn
Citizens reiterates Immix Biopharma stock rating on trial enrollment By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on trial enrollment - Investing.com
Immix Biopharma completes enrollment in AL amyloidosis trial By Investing.com - au.investing.com
Immix Biopharma (IMMX) price target increased by 25.64% to 16.66 - MSN
Immix Biopharma Completes NEXICART-2 Enrollment for NXC-201 - tipranks.com
Immix rises as Morgan Stanley starts with bullish view on CAR-T therapy - MSN
Immix completes enrollment in NEXICART-2; topline results expected Q3 2026 - TradingView
[8-K] Immix Biopharma, Inc. Reports Material Event - Stock Titan
Immix Biopharma Completes Enrollment for Key AL Amyloidosis Trial - National Today
Immix Biopharma (NASDAQ:IMMX) Stock Price Expected to Rise, Mizuho Analyst Says - MarketBeat
Immix Biopharma Inc Announces Enrollment Completion Of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2 And Upcoming Milestones - marketscreener.com
Immix Biopharma completes enrollment in AL amyloidosis trial - investing.com
Immix Biopharma, Inc. has announced the successful completion of patient enrollment for its Nexicart-2 trial in relapsed/refractory AL amyloidosis, which supports the Biologics License Application (BLA). - Bitget
Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones - The Manila Times
Mizuho raises Immix Biopharma stock price target on cash position By Investing.com - Investing.com India
Mizuho raises Immix Biopharma stock price target on cash position - investing.com
Should I trade or invest in Immix Biopharma Inc2026 Breakouts & Breakdowns & Proven Capital Preservation Tips - baoquankhu1.vn
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Immix Biopharma, Inc. 2025 Annual Report Amendment: Financial Statements, Auditor Correction, and Company Overview - Minichart
Immix Biopharma (NASDAQ:IMMX) Issues Quarterly Earnings Results - MarketBeat
Immix Biopharma (NASDAQ: IMMX) widens 2025 loss but ends year with $100M cash - stocktitan.net
Mizuho raises Immix Biopharma stock price target to $15 on cash position - Investing.com Australia
Mizuho raises Immix Biopharma stock price target to $15 on cash position By Investing.com - za.investing.com
Citizens Jmp Reaffirms Market Outperform Rating for Immix Biopharma (NASDAQ:IMMX) - MarketBeat
H.C. Wainwright raises Immix Biopharma price target to $15 By Investing.com - Investing.com India
Immix Biopharma (NASDAQ:IMMX) Given New $15.00 Price Target at HC Wainwright - MarketBeat
H.C. Wainwright raises Immix Biopharma price target to $15 - Investing.com
Citizens reiterates Immix Biopharma stock rating on drug progress By Investing.com - Investing.com South Africa
Citizens reiterates Immix Biopharma stock rating on drug progress - investing.com
Immix Biopharma (NASDAQ:IMMX) Now Covered by Morgan Stanley - Defense World
Immix Biopharma, Inc. Files Form 8-K Announcing Amendment to ATM Agreement and Legal Opinion – March 25, 2026 - minichart.com.sg
Immix Biopharma, Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Immix Biopharma’s NXC-201: Next-Generation CAR-T Therapy for AL Amyloidosis and Other Serious Diseases – Pipeline, Strategy, and Clinical Advances - Minichart
Millennium Management LLC Acquires Significant Stake in Immix Bi - gurufocus.com
Finanzdaten der Immix Biopharma Inc-Aktie (IMMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Immix Biopharma Inc-Aktie (IMMX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Morris Gabriel S | CFO |
Dec 10 '25 |
Buy |
6.58 |
770 |
5,067 |
291,429 |
| Rachman Ilya M | CEO and Chairman |
Sep 17 '25 |
Buy |
2.02 |
2,500 |
5,050 |
1,140,937 |
| Morris Gabriel S | CFO |
Sep 16 '25 |
Buy |
1.97 |
2,600 |
5,122 |
290,659 |
| Rachman Ilya M | CEO and Chairman |
Jun 18 '25 |
Buy |
2.29 |
2,178 |
4,999 |
1,138,437 |
| Morris Gabriel S | CFO |
Jun 18 '25 |
Buy |
2.28 |
2,225 |
5,071 |
288,059 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):